The Duplex Interaction of Microbiome with Chemoradiation and Immunotherapy: Potential Implications for Colorectal Cancer
- 11 Downloads
Purpose of review
Gut microbiota has the ability to modify the metabolism of wide array of therapeutic drugs. Current treatment modalities used in colorectal cancer have a narrow therapeutic index with a side effects profile that decreases tolerance to these treatments and adversely affects treatment outcome. Harnessing the gut microbiota ability to modify oncotherapeutic drugs metabolism and hence efficacy, could be potentially used to improve treatment outcomes in colorectal cancer patients. This review will shed lights on important findings from recent microbiome interaction studies which would hopefully serve as a useful tool to guide future translative colorectal cancer research.
Recent advances in microbiome studies have revealed an interesting aspect of gut microbes’ carcinogenic properties in dysbiotic gut environment. Microbiota niche in colorectal cancer can also modify efficacy and toxicity profile of different oncotherapeutic treatment modalities from chemoradiotherapy to immunotherapy. Conversely, each of these treatment modalities has numerous effects on the gastrointestinal flora, causing changes in the gut microbial community that affects host morbidity and mortality.
Symbiotic gut microbiota is an incredible functioning organ that maintains essential aspects of our homeostasis and immunity. According to the recent body of literature, they also can modify efficacy of many therapeutic drugs including oncotherapy. Considering that unexplainable variable treatment outcomes as well as variable tolerance to treatment have been observed in colorectal cancer patients, studying gut microbiota modulatory effects on oncotherapy might be a feasible approach to explain this phenomenon.
KeywordsChemotherapy Radiotherapy Chemoradiation Cancer Oncology Colon Microbiome Microbiota Pharmacomicrobiomics Gastrointestinal Oncotherapy
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 22.Bajic JE, et al. From the bottom-up: chemotherapy and gut-brain axis dysregulation. Front Behav Neurosci. 2018, 2018;12:104. https://doi.org/10.3389/fnbeh.2018.00104.
- 23.• Chang CW, Liu CY, Lee HC, et al. Lactobacillus casei variety rhamnosus probiotic preventively attenuates 5-fluorouracil/oxaliplatin-induced intestinal injury in a syngeneic colorectal Cancer model. Front Microbiol. 2018;15(9):983 An animal model study validating the positive protective impact of modulating the gut microbiome in the setting of 5FU based chemotherapy. Attenuation of intestinal injury seen as a result of probiotic supplementation.CrossRefGoogle Scholar
- 24.Din MO, Danino T, and Prindle A, et al (2016) Synchronized cycles of bacterial lysis for in vivo delivery Nature 536 81–85 https:// doi.org/10.1038/nature18930.
- 29.• Gerassy-Vainberg S, Blatt A, Danin-Poleg Y, et al. Radiation induces proinflammatory dysbiosis: transmission of inflammatory susceptibility by host cytokine induction. Gut. 2018;67:97–107 This study illustrates the impact of radiation on shifting the microbial niche toward dysbiosis. This was shown to highly correlating with radiation induced intestinal inflammation.CrossRefGoogle Scholar
- 33.Ferreira MR, Muls A, Dearnaley DP, Andreyev HJ. (2014). Microbiota and radiation-induced bowel toxicity: lessons from inflammatory bowel disease for the radiation oncologist. Lancet Oncol. doi:Google Scholar
- 34.Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol. 2014;32:189–225. https://doi.org/10.1146/annurev-immunol-032713-120136.CrossRefGoogle Scholar
- 36•.Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359:91–7. https://doi.org/10.1126/science.aan3706 This study provides backing evidence that quality and quantity of the gut microbiome impact responses to check point inhibitors.CrossRefGoogle Scholar
- 38.Frank M, Hennenberg EM, Eyking A, et al. Europe PMC Funders Group Europe PMC Funders Author Manuscripts TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol. 2015;194:1983–95. https://doi.org/10.4049/jimmunol.1402481.
- 39.Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104–8. https://doi.org/10.1126/science.aao3290.